Remdesivir for Covid-19 pneumonia in patients with severe chronic kidney
disease: Case series and review of the literature
- Ahmad Al Bishawi
, - Hamad Abdel Hadi,
- Eman Elmekaty,
- Musaed Al Samawi,
- Arun Nair,
- mohamed aboukamar,
- Muna AlMaslamani,
- Alaaeldin Abdelmajid
Abstract
Remdesivir was the first antiviral agent to receive FDA authorization
for severe COVID-19 management, which restricts its use with severe
renal impairment due to concerns that active metabolites might
accumulate, causing renal toxicities. With limited treatment options,
available evidence on such patient groups is important to assess for
future safety.26 Dec 2021Submitted to Clinical Case Reports 28 Dec 2021Submission Checks Completed
28 Dec 2021Assigned to Editor
03 Jan 2022Reviewer(s) Assigned
15 Jan 2022Review(s) Completed, Editorial Evaluation Pending
23 Jan 2022Editorial Decision: Revise Minor
26 Jan 20221st Revision Received
27 Jan 2022Submission Checks Completed
27 Jan 2022Assigned to Editor
27 Jan 2022Review(s) Completed, Editorial Evaluation Pending
01 Feb 2022Editorial Decision: Accept
